COVID VACCINE

 Covishild/covaxin...

      

vaccination is crucial right now:

The drive, one of the largest in the world comes at a time when the country is reeling under a terrible crisis spawned by the mutant viruses and second wave of infections.

 The vaccines are available in India right now :

Currently, there are two vaccines available to the public- Bharat Biotech's Covaxin and Serum Institute- Oxford University-AstraZeneca's Covishield vaccine. Other vaccines, including Sputnik V, are soon touted to be made available.

Is one better than the other?????(simply says know both are better at this stage)

Covaxin and Covishield are both homegrown vaccines that have driven India's vaccination drives. While Covaxin is fully made, developed and produced in India, Covishield is manufactured by Pune-based Serum Institute of India.

Yet, there are some dissimilarities and benefits which peg them apart. Covishield or the Oxford-AstraZeneca jab remains to be the popular choice, used in maximum countries. Covaxin, on the other hand, is now considered to be one of the most effective and tolerant vaccines against mutant strains. But, do the differences make one better than the other?

Manufacturing:

Covaxin and Covishield are both similar vaccines made using inactive/modified versions of the virus.

While Covishield, which is manufactured and marketed by Serum Institute of India is a viral vector vaccine that uses an adenovirus found in Chimpanzees, ChAD0x1, to deliver spike proteins and mount a tolerable immune response in response to a live virus.

On the other hand, Covaxin is also a traditionally made vaccine but uses an inactive viral strain. It makes use of a dead virus that drafts an immune response.

Number of doses for each vaccine:

Both the vaccines work as two-dose vaccines, administered weeks apart.

Both are administered in upper arm muscles

Effectiveness:

When it comes to mapping effectiveness, both the vaccines have been found to be well-effective, matching WHO standards and prompting definite immune responses.

Covishield, which wrapped up trials in November last year carries an efficacy rate of 70%, which could be further scaled up to 90% if the dosing is given half a dose, followed by a full dose a month later. The tolerability and protection have also been found to be well-suited and thought to reduce the risk of symptomatic infections and speed up recovery timelines, which has been much talked about recently.

Covaxin, a late entrant in the race, had completed major trials by the end of February. As per interim results and clinical studies, the Bharat Biotech vaccine was found to carry over 78% efficacy. Additionally, there has also been clinical evidence that suggests that Covaxin could reduce severity and mortality risk by a whopping 100 per cent.

Conclusion:

              "All is well that ends well",I recommend all of you who read this article please get vaccination and keep the infection away.

Advice:

         The person who with some health issues for a longer period please consult a doctor before taking vaccination...

            

        Thanking you ❤️...

.